NCT02608125: A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors

NCT02608125
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only patients with FGFR 1, 2, 3, or 4 genetic alterations will be eligible for the expansion phase (Part B)
Exclusions: 
https://ClinicalTrials.gov/show/NCT02608125

Comments are closed.

Up ↑